• Pharma revenues grew by 10% to HUF 220bn in Q1 2025, as GenMed, BIO and Vraylar sales grew double-digit, while WHC saw a strong base effect. Ex-Fx revenue growth was 6%.
• Net profit came in strong at HUF 68bn, similar to the year-ago level, while free cash-flow increased by 14% to HUF 60bn.
• Working hard to make medicines affordable to a wider range of patients by key events around the denosumab and tocilizumab biosimilars, a semaglutide co-development agreement and multiple sclerosis launches
• Full-year guidance of around 10% increase (ex-FX) in both revenues and Clean EBIT is maintained

Budapest, 13 May 2025 - Gedeon Richter Plc. (“Richter”) announced today its Q1 2025 financial results.

Pharma revenues increased by 10% to HUF 220bn in Q1 2025. Excluding currency changes (ex-FX), revenue growth was 6%, slightly below the full-year guidance, primarily due to a high base effect (large pre-shipments boosted sales a year ago, mostly in the WHC segments and in the APAC region).

• CNS revenues increased by 13% in Q1 2025 YoY on the back of continued robust growth in Vraylar royalty income (+14%). Reagila^® sales were flat YoY, temporarily held back due to delivery schedules and a partner change in Australia.
• Women’s Healthcare revenues were up by 6% in Q1 2025 YoY. The growth was relatively modest due to a strong base effect, as large pre-shipments took place in H1 2024, primarily in contraceptives and menopause in the APAC region and North America. Western and Eastern European sales grew double-digit in Q1, and most of the leading brands (Ryeqo^®, Drovelis^®, Lenzetto^®, EVRA^®) managed to keep their strong momentum.
• BIO revenues continued to grow at double-digit rates, driven by CDMO sales on the back of the higher capacity. Teriparatide sales were flat due mainly to temporarily reduced shipments to commercial partners.
• GenMed revenues rose by an impressive 12% in Q1 2025 YoY, helped by a lower base, some FX tailwind and positive price impact as well as higher volumes. FX-adjusted growth was also remarkable around 9%.

Gross profit (pharma) grew by 10% to HUF 154bn, while gross margin was marginally lower (-0.2ppt) at 70.0% in Q1 2025.

Clean EBIT (pharma) increased by 8% in Q1 2025 to HUF 69bn. If adjusting for FX (ex-FX) Clean EBIT rose by 4% to EUR 167mn. CNS was the key driver of Clean EBIT growth on the back of double-digit Vraylar sales growth and GenMed Clean EBIT also rose double-digit. WHC profitability was affected by the high base and an increase in R&D and S&M expenses. BIO losses were broadly unchanged, as revenue growth was offset by lower gross margin, while a decline in R&D expenses was offset by the lack of milestone income and higher other opex.

Reported EBIT came in at HUF 68bn in Q1 2025, rising 7% YoY.

Net profit (attributable to the owners of the parent) was HUF 68bn in Q1 2025, almost unchanged compared to the year-ago level, as net financials again added to the bottom line.

Free cash flow (before M&A) amounted to HUF 60bn in Q1 2025, increasing by 14% reflecting stronger operating profitability, declining capex and a smaller increase in Net Working Capital than a year ago. No major capital outflows (M&A transactions, dividends) took place in Q1, hence FCF added to the net cash position. The AGM approved the Board’s proposal to pay out HUF 93bn dividends from 2024 after-tax profits. The payment will take place in June 2025.

Richter is working hard to make medicines affordable to a wider range of patients. The positive CHMP opinion on our denosumab biosimilars, the filing of our tocilizumab biosimilar in Europe, the signing of a co-development and license agreement with Adalvo for a proposed bioequivalent to Semaglutide injection (a GLP-1 receptor agonist) and the recent and upcoming launches of multiple sclerosis products are all important steps in executing our long-term strategy in the affordable businesses to broaden access to medicines to a wider range of patients.

Our international CSR program was launched in Q1. In coordination with Hungarian and local NGOs we built and opened a safe house (“GR House of Hope”) for women in Bamako (Mali) as part of our commitment to make women’s life better globally.

Gábor Orbán, CEO commented the results:

“We continued to grow our business in 2025 to date, as our GenMed, BIO sales and the Vraylar royalty income sustained double-digit increase. Women’s Healthcare was affected by a high base boosted by pre-shipments a year ago, at the same time FX remained a tailwind across the board. I am very proud of those important steps we made in the last few months in executing our affordable strategy. We received a positive CHMP opinion on our denosumab biosimilars, we filed our tocilizumab biosimilar in Europe, we signed a co-development and license agreement with Adalvo for a semaglutide injection and we are launching multiple sclerosis products in Europe, all to broaden access to medicines to a wider range of patients.“

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

For further information:

Investors: Róbert Réthy, CFA                                                                      +36 20 342 2555

Media: Zsuzsa Beke                                                                                        +36 20 916 4507